Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD
Study
Inclusion/Exclusion Baseline
Description Intervention
Criteria/Population Measures Outcomes
Author:
Intervention:
Inclusion criteria: Overall ratings: Overall ratings:
Coniglio et al., Porcine secretin admini- • Met DSM-IV criteria for CARS total score, CARS total score,
2001
stered IV (test dose of 0.1 diagnosis of autism mean ± SD: 3 weeks, mean ±
Country: ml; if no acute
• CARS score ≥ 30 G1: 42.4 ± 5.4
US
anaphylactic reaction in • Total PLS-3 ≤ 60 months G2: 41.3 ± 6.3
Practice 1 minute, 2.0 CU/kg Exclusion criteria: GARS autism
setting:
(maximum of 75 CU) • See inclusion criteria quotient, mean ±
Academic administered over 1 Age, months ± SD: SD:
Intervention minute)
G1: 84.6 ± 25.2
G1: 104.1 ± 15.4
setting:
Assessments:
G2: 83.5 ± 28.9
G2: 108.1 ± 11.9
Clinic
1 pre-injection and 2 post- Mental age:
PLS total age,
Enrollment injection developmental/ NR
months ± SD:
period:
behavioral assessments: Gender, %:
G1: 15.4 ± 9.5
NR
Presence or absence of Male:
G2: 22.0 ± 12.8
Funding: normal development G1: 73
Children’s in early infancy and any G2: 77
Healthcare of associated gastro- Female:
Atlanta
intestinal disturbances G1: 23
Foundation Performed by 4
G2: 27
Author industry evaluators (2 clinical Race/ethnicity, %:
relationship psychologists, 1 White:
disclosures: advanced psychology G1: 80
NR
graduate student, 1 G2: 77
Design: developmental
African American:
RCT (method of pediatrician)
G1: 17
randomization not Groups:
G2: 13
described) G1: secretin
Other:
G2: placebo (saline) G1: 3
Co-interventions held G2: 10
stable during treatment: SES:
No; approximately 7% of Maternal education: NR
parents indicated that Household income: NR
they had started a new Diagnostic approach:
treatment regimen since In Study
beginning the study Diagnostic tool/method:
Frequency of contact DSM-IV criteria were
during study:
assessed for each child to
At screening and provide documentation of
injection, and at 3 and 6 the diagnosis of autism
weeks post-injection before study entry
Concomitant therapies: Diagnostic category, %:
NR
Autism:
N at enrollment: G1: 50
G1: 30
G2: 52
G2: 30
PDD:
N at follow-up:
G1: 24
G1: 28
G2: 14
G2: 29
SD:
G1: 39.2 ± NR
G2: 41.9 ± NR
G1/BL: P = 0.051
CARS total score,
6 weeks, mean ±
SD:
G1: 41.8 ± NR
G2: 41.7 ± NR
ANOVA: time &
treatment (P =
NS)
Improvement in
CARS total scores
BL to 6 weeks, %:
G1: 36
G2: 28
G1/G2: P = NS
GARS autism
quotient, 3 weeks,
mean ± SD:
G1: 92 ± NR
G2: 99 ± NR
GARS autism
quotient, 6 weeks,
mean ± SD:
G1: 92 ± NR
G2: 99 ± NR
ANOVA: time (P =
0.000) treatment
(P = NS)
PLS total age, 3
weeks, months ±
SD:
G1: 16 ± NR
G2: 21 ± NR
PLS total age, 6
weeks, months ±
SD:
G1: 17 ± NR
G2: 21 ± NR
ANOVA: time &
treatment (P =
NS)
Coniglio et al.,
Autism and PDD:
Social skills:
2001 (continued)
G1: 24
Parent reported
G2: 36
changes in social
Aspergers:
behavior or
G1: 0
language, %:
G2: 0
G1: 67
Other characteristics:
G2: 42
DSM-IV diagnostic
Medical:
characteristics, %:
Parent-reported
C-391